Biogen Inc. (BIIB)

199.65
NASDAQ
Prev Close 193.09
Day Low/High 194.50 / 199.78
52 Wk Low/High 187.16 / 468.55
Exchange NASDAQ
Shares Outstanding 146.45B
Market Cap 28.28B
P/E Ratio 8.89
Div & Yield N.A. (N.A)
Two Giants Blindsided by Major Trends

Two Giants Blindsided by Major Trends

McDonald's and GlaxoSmithKline are fighting against major turns of the tide.

Taking a Shot at a Monitise Long

Taking a Shot at a Monitise Long

This may be one of only two technical buying opportunities in 2014. 

BIIB Investor Mtg.

The Lesson of Today's Session

The Lesson of Today's Session

Become more aggressive about the real valuations of companies.

No Joy in Shortville

No Joy in Shortville

Shorts take much more homework than longs.

Biogen Idec upgraded at JP Morgan

Biotechs Flash the Green Light

Biotechs Flash the Green Light

After a decline, the sector has built a base, and these names are breaking out.

In Fact, There Is No Bubble, Part 4

In Fact, There Is No Bubble, Part 4

Away from the techs and the biotechs, you will find an astounding uniformity among stocks.

Deutsche Healthcare Conf.

Fitz Bits: Be a Blank Slate

Fitz Bits: Be a Blank Slate

Take a step back from the noise and use only what you see on the charts.

The Blueprints for this Market (Part 5)

The Blueprints for this Market (Part 5)

When it gets as bad as it is now, we tend not to even care if a company is profitable.

Miracle Drug May Be Ailing Gilead

Miracle Drug May Be Ailing Gilead

Its potent hepatitis C treatment is not a boon for shareholders.

Scoping the Earnings Trades

Scoping the Earnings Trades

Not seeing much on Biogen, but Yum! Brands looks playable.

Netflix and Allergan Lead the Way

Netflix and Allergan Lead the Way

Internet and biotech stocks are trading as a cohort right now.

Get Used to the New Market Reality

Get Used to the New Market Reality

Algos think faster and react faster than humans can.

A Blueprint for Highflier Stability

A Blueprint for Highflier Stability

Cautionary tales that the IPO window might be closing at last.

Fitz Bits: The Biotech Wreck

Fitz Bits: The Biotech Wreck

These stocks are broken -- and you can't un-break them

Henry Gambell Analysis: E-mini S&P, VIX, CELG, BIIB, GLD, SLV & XME

Henry Gambell Analysis: E-mini S&P, VIX, CELG, BIIB, GLD, SLV & XME

Today's Big Idea covers resistance in the S&P along with key signals in the VIX, and update on CELG and thoughts on precious metals and fresh signals in XME.

Biogen Idec upgraded at BMO

Biogen Idec numbers increased at Leerink

A Surprising Leaderboard

A Surprising Leaderboard

These sectors have shown some fight.

The Tyranny of Futures Goes Away

The Tyranny of Futures Goes Away

And valuation of individual stocks comes back into play.

I'll Still Trumpet These Stocks

I'll Still Trumpet These Stocks

I like living, breathing examples of growth stocks going right.

Three Plays on the Table

Three Plays on the Table

I'm using the market's push lower to buy strong charts.

Who's Getting Busy Living?

Who's Getting Busy Living?

These types of companies are winners today.

Healthcare Holding Strong

Healthcare Holding Strong

It's clear that bulls in this sector aren't weak hands.

Giving Biogen Another Go

Giving Biogen Another Go

Here's what we'd need to see before trying a reentry.

Why Tech Works

Why Tech Works

There are quite a few reasons to be optimistic.

Biogen Idec numbers raised at Goldman

A Healthy Trade in Biogen

A Healthy Trade in Biogen

I'm looking at it closely for a buy entry.